Short answer
Janux Therapeutics, Inc. (JANX) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $10M with net income of −$22M.
Q2 2026 key financials · XBRL
- Revenue
- $10M
- +175.0% QoQ
- Net income
- −$22M
- +35.1% YoY · +9.8% QoQ
- Operating margin
- -308.7%
- EPS (diluted)
- −$0.35
- +36.4% YoY · +10.3% QoQ
Source: XBRL data from the Janux Therapeutics, Inc. (JANX) Q2 2026 10-Q on SEC EDGAR. USD.
Janux Therapeutics, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Collaboration revenue $10.3M, up $10.3M YoY from $0, driven by BMS Agreement research services
- Net loss $22.0M vs $33.9M YoY; operating margin not disclosed
- R&D expense $31.0M, down $3.7M YoY; highest program spend JANX007 at $6.2M
- Cash, equivalents, restricted cash and short-term investments $971.7M as of June 30, 2026
- Operating cash flow $0.1M vs $(40.8)M YoY; $30.0M net short-term investment purchases
- Existing liquidity expected to fund operations and capital expenditures through at least the next 12 months; continued losses anticipated
Risk Factors
- April 2026 JANX008 discontinuation after Phase 1a, reflecting insufficient activity versus other pipeline programs
- Cash, equivalents and short-term investments $970.9 million at June 30, 2026, funding operations for at least 12 months
- Additional capital required for regulatory approval and commercialization, creating dilution or potential program reductions
- Data-privacy noncompliance exposure, including regulatory actions, class claims, mass arbitration, fines and operational disruption
- Novel immuno-oncology technologies face rapid competitor innovation and limited clinical data for JANX007, JANX011 and JANX014
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Janux Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.